Skip to content
10-Q

Quarterly Report

Merck & Co., Inc. MRK

0001628280-25-021834

← back to feed
Filed
May 2, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 2.51B sh
Long Term Debt Q1 2025 · Mar 31, 2025 $33.48B
Long Term Debt Q1 2025 · Dec 31, 2024 $34.46B
Short Term Debt Q1 2025 · Mar 31, 2025 $1.36B
Short Term Debt Q1 2025 · Dec 31, 2024 $2.65B
Cash And Equivalents Q1 2025 · Mar 31, 2025 $8.63B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $13.24B
Stockholders Equity Q1 2025 · Mar 31, 2025 $48.34B
Stockholders Equity Q1 2025 · Dec 31, 2024 $46.31B
Current Liabilities Q1 2025 · Mar 31, 2025 $25.17B
Current Liabilities Q1 2025 · Dec 31, 2024 $28.42B
Current Assets Q1 2025 · Mar 31, 2025 $35.5B
Current Assets Q1 2025 · Dec 31, 2024 $38.78B
Total Assets Q1 2025 · Mar 31, 2025 $115.12B
Total Assets Q1 2025 · Dec 31, 2024 $117.11B
Shares Diluted Q1 2025 · Mar 31, 2024 2.54B sh
Stock Repurchased Q1 2025 · Mar 31, 2024 $122M
Dividends Paid Q1 2025 · Mar 31, 2024 $1.95B
Capex Q1 2025 · Mar 31, 2024 $861M
Operating Cash Flow Q1 2025 · Mar 31, 2024 $3.09B
Eps Diluted Q1 2025 · Mar 31, 2024 $1.87
Eps Basic Q1 2025 · Mar 31, 2024 $1.88
Sga Expense Q1 2025 · Mar 31, 2024 $2.48B
Rd Expense Q1 2025 · Mar 31, 2024 $3.99B
Net Income Q1 2025 · Mar 31, 2024 $4.76B
Cost Of Revenue Q1 2025 · Mar 31, 2024 $3.54B
Revenue Q1 2025 · Mar 31, 2024 $15.78B